The New York Times on New Advances in Prostate Cancer Treatment, including Exelixis' Cabozantinib

The New York Times - June 27, 2011

The New York Times's Andrew Pollack provides insight into new advances in the developement of prostate cancer drugs. He highlights the San Francisco biotech Exelixis for discovering a means of eliminating bone lesions resulting from prostate cancer via its new investigational compound, cabozantinib.

"Some of the most exciting advances, doctors say, are in the area of fighting the spread of prostate cancer to the bone. Such bone metastases are very common in men with advanced prostate cancer and account for most of the death and disability from the disease."

"Cabozantinib, an experimental drug being developed by Exelixis, seems to be able to virtually eradicate bone metastases in some patients, at least as measured by bone scans, something no other drug has done."

Read the full story here.

For additional coverage of cabozantinib data from the ASCO Annual Meeting, please see the following: Reuters | The Street | Xconomy